Kornimate/medical-research-clean huggingface dataset:
the impact of the fluid resuscitation on the venous volume and flow characteristics in hypovolemic shock

Conditions: the Study Focuses on the Subgoup of Patients With Decreased Effective Blood Volume eg. Trauma Surgical and Non Surgical Patients

Summary: we hypothesis that in various situation when the effective blood volume decreased the venous volume flow characteristics change according to the fluid resuscitation

patients with clinical signs of loss of the effective blood volume will undergo ultrasound examination of several major veins. the purpose of this examination is to determine vein volume(size) and flow. the ultrasound examination will be done before fluid resuscitation, after fluid administration,and three days after admission

Eligibility criteria:
inclusion criteria: * age \> 18 years old * decreased effective blood volume * systolic blood pressure \< 100 * pulse rate \> 110 exclusion criteria: * age \<18 years old * pregnancy * patient requires urgent surgical intervention

Keywords: decreased blood volume vein volume flow ultrasound exam
patients overexposed for a prostate adenocarcinoma

Conditions: Prostate Adenocarcinoma

Summary: background: between 2000 and 2006, 433 patients were overexposed (8% to 10%) during a course of conformal radiotherapy for a prostate adenocarcinoma in jean monnet hospital, epinal, france. among them, twenty four patients received an additional mean dose about 20%, due to an inappropriate use of the treatment planning system. severe adverse events (proctitis, cystitis, and tissue necrosis) have occurred among most of these overexposed patients. we propose to develop several research programs in order to increase the scientific knowledge on iatrogenic effects related to overexposure of ionizing radiation, by studying their relationship with dosimetric, clinical, biologic and genetic characteristics. aim of the study: to correlate the received doses, the volume of irradiated normal tissues, the events, with biologic, phenotypic and genetic data. primary study endpoint: incidence and severity of adverse events related to radiotherapy (according to soma - lent and ctcae scales).

secondary study endpoint: * correlation between adverse events and radiation doses with biologic, phenotypic and genetic data. * evaluation of t-lymphocyte apoptosis to predict radiation-induced late toxicity * gene associations with risks for adverse events related to radiotherapy * levels of circulating microparticles and bystander effect after irradiation inclusion criteria: consecutive patients treated for a prostate adenocarcinoma in the radiation department of the jean monnet hospital between 2000 and 2006. potential. better identification of patients at high risk of adverse events related to radiotherapy.

Eligibility criteria:
inclusion criteria: * provision of informed consent * patient treated for prostate adenocarcinoma and overexposed during radiotherapy in a prostate adenocarcinoma in the radiation department of the a prostate adenocarcinoma in the radiation department of the jean monnet hospital/ service de radiotherapies between 2000 and 2006 exclusion criteria: * no provision of informed consent * patient with disease worsening and in incapacity to move about to chjm

Keywords: radiotherapy biologically effective dose radiation injury
spironolactone combined with captopril and carvedilol for the treatment of pulmonary arterial hypertension

Conditions: Hypertension, Pulmonary

Summary: the purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with an ace inhibitor (captopril) and a beta-blocker (carvedilol) is effective in reverse pulmonary artery remodeling in patients with pulmonary arterial hypertension (pah)secondary to congenital heart disease

the pathogenesis of pah involves multiple mechanisms. however, three common factors are thought to cause the increased pulmonary vascular resistance that characterizes this devastating disease: vasoconstriction, pulmonary vascular proliferation and remodeling, and thrombosis in situ. advances in our knowledge of the molecular mechanisms involved in pah suggest that endothelial dysfunction with chronic impaired production of vasoactive mediators plays a key role. reduced production of vasoactive mediators, such as nitric oxide (no) and prostacyclin, along with prolonged overexpression of vasoconstrictors such as endothelin-1 (et-1), not only affect vascular tone but also promote vascular remodeling. thus, these substances represent logical pharmacological targets. animal studies showed et-1 could stimulate aldosterone secretion in different species, both in vivo and in vitro. this stimulation involves the et-b alone and both et-a and et-b receptor subtypes in rats and humans. animal studies also showed spironolactone combined with ace inhibitor could normalize blood pressure, prevents upregulation of vascular et-1, restore nitric oxide (no)-mediated endothelial dysfunction. beta-blockers have ability to reduce dp/dt in pulmonary artery, as well as left ventricle, thus prevent further damage to the dysfunctional endothelium. furthermore, we observed from our practice that the aforementioned therapy could lower pulmonary artery pressure in patents with pulmonary hypertension secondary to left ventricular dysfunction. thus, we hypothesize spironolactone combined with ace inhibitor and beta-blocker has the ability to reverse remodeling of pulmonary artery in pah patients.

Eligibility criteria:
inclusion criteria: * a mean pulmonary artery pressure higher than 25 mm hg or, when estimated by echocardiography, pulmonary artery pressure more than half the systemic artery pressure * congenital systemic-to-pulmonary shunts

Keywords: aldosterone antagonists, spironolactone, captopril carvedilol
a study to evaluate the safety and efficacy of ct1812 in early alzheimer's disease

Conditions: Early Alzheimer's Disease

Summary: this is a multicenter randomized, double-blind, placebo-controlled phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of ct1812 compared to placebo in participants diagnosed with early alzheimer's disease.

this is a multicenter randomized, double-blind, placebo-controlled phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of ct1812 compared to placebo for approximately 18 months (72 weeks) in approximately 540 participants diagnosed with early alzheimer's disease participants will be randomized 1:1:1 to receive either 100mg or 200mg of ct1812 or placebo. ct1812 or placebo will be administered as 2 capsules to be taken orally once daily.

Eligibility criteria:
inclusion criteria: 1. ages 50-85 years. 2. diagnosis of either mci due to ad or mild ad dementia. 3. mmse 20-30 (inclusive). 4. amyloid pet scan of the brain or csf biomarkers consistent with ad. 5. neuroimaging (mri) obtained during screening consistent with the clinical diagnosis of alzheimer's disease, as based on central read. exclusion criteria: 1. screening mri of the brain indicative of significant abnormality. 2. clinically significant abnormalities in screening laboratory tests. 3. clinical or laboratory findings consistent with: 1. other primary degenerative dementia, (dementia with lewy bodies, fronto-temporal dementia, huntington's disease, creutzfeldt-jakob disease, down syndrome, etc.). 2. other neurodegenerative condition (parkinson's disease, amyotrophic lateral sclerosis, etc.). 3. other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin b12, other laboratory values etc.) 4. a participant known to be actively infected with hepatitis b or hepatitis c at screening. history of acute/chronic hepatitis b or c and/or carriers of hepatitis b (seropositive for hepatitis b surface antigen \[hbsag\] or anti-hepatitis c \[hcv\] antibody). participants who have evidence of resolved hepatitis infection (e.g., hcv rna negative) may be considered following discussion with the medical monitor. 5. a current dsm-v diagnosis of active major depression or gds \> 6, schizophrenia, or bipolar disorder.

Keywords: alzheimer's disease
pioglitazone vs. insulin glargine in the treatment of secondary drug failure in type 2 diabetes

Conditions: Type 2 Diabetes; Secondary Drug Failure

Summary: pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.

the present study was undertaken to assess differences in how insulin glargine vs. pioglitazone affect: * beta-cell function as measured by proinsulin/insulin, homeostasis model assessment for insulin secretion (homa β-cell) and glucagon stimulated c-peptide test * insulin sensitivity as measured by adiponectin, homeostasis model assessment for insulin resistance (homa-ir) and insulin tolerance test and * surrogate markers of cardiovascular disease as measured by bnp, nt-pro bnp and plasma lipid profile as add-on therapy in patients with t2d and secondary drug failure. the patients' satisfaction with each treatment was also surveyed.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * inadequately controlled on 50% of maximal-dose of an insulin secretagogue and metformin exclusion criteria: * heart failure (nyha ii-iv)
reduction of oxalate and inflammation by hemodiafiltration vs. hemodialysis

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: the health care burden of ckd is substantial and growing with 10-15% of the population affected in both developed and developing countries. it is well established that ckd is associated with systemic inflammation, which promotes cardiovascular disease and body wasting. however, causal therapies to treat systemic inflammation, and treat its adverse consequences remain sparse. as kidney function declines in all forms of ckd, oxalate levels increase in the plasma, leading to increased systemic exposure to oxalate and consequent tissue injury. work from the investigators has shown that elevated plasma oxalate levels activate the nlrp3 inflammasome which in turn leads to the processing and release of cytokines. the investigators seek to test the hypothesis that oxalate contributes to the systemic inflammation observed in patients with end-stage renal disease (esrd). the investigators plan to define the association between plasma oxalate levels and signs of systemic inflammation in patients on hemodialysis. in a second step the investigators will examine whether hemodiafiltration lowers plasma oxalate more efficiently than hemodialysis and reduces signs of systemic inflammation. confirmation of the hypothesis may lead to the identification of oxalate as a novel therapeutic target for interventional trials aimed at reducing plasma oxalate in patients with esrd.

the positive interaction between diffusive and convective flux has suggested that hemodiafiltration (hdf) has a higher oxalate extraction rate as compared with hemodialysis (hd). however, it has not been evaluated whether hdf can lower predialysis oxalate levels below the level of supersaturation. by using an intra-individual approach with the inclusion/exclusion criteria listed for the study, we plan to determine plasma oxalate and cytokine levels in 20 patients (10 on regular duration hd, 10 patients on extended duration hd) before dialysis. subsequently, patients will be switched to hdf and plasma oxalate concentration and cytokines will be analyzed again two weeks following hdf treatment. plasma oxalate (pox) will be measured at beginning of treatment, mid, end and 2 hrs post treatment (to determine rebound) in order to provide oxalate kinetics on hd/hdf treatment. cytokines will only be measured pre hd/hdf treatment to assess steady state inflammation.

Eligibility criteria:
inclusion criteria: * blood flow ≥ 250 ml/min * dialysate flow ≥ 500 ml/min * urinary excretion \< 400 ml/24h * duration of dialysis ≥ 4h * on hdf/hd treatment for ≥ 4 weeks * extended hdf/hd for ≥ 4 weeks exclusion criteria: * recirculation (online measurement) \> 15% * single needle dialysis or single lumen catheter * substitution volume of \< 20l on hdf

Keywords: oxalate inflammation hemodiafiltration hemodialysis oxalate blood sample
fucidin® cream in the treatment of impetigo

Conditions: Impetigo

Summary: to investigate the clinical and bacteriological efficacy of fucidin® cream in the treatment of impetigo in paediatric patients. to assess the validity of in vitro susceptibility-testing of s. aureus to fusidic acid as a prediction of clinical and bacteriological outcome in impetigo patients treated with fucidin® cream. to investigate the genetic relationship between s. aureus-strains isolated from impetigo patients.


Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of impetigo, * patients aged 2-11 years, * patients of either sex, * patients whose parent(s) has(ve) provided written consent, and * patients with a severity score of 1 for at least one of the following signs: pustules/infected bullae, erythema and infiltration/induration. exclusion criteria: * patients with other active inflammatory dermatitis at the area of impetigo, * patients with a temperature above 38.5 c rectally (or equivalent), or * patients who have been administered topical or systemic fucidin® or other antibacterial agents within the previous 4 weeks.
cbd, nutrient metabolism and energy intake

Conditions: Glucose Metabolism Disorders (Including Diabetes Mellitus); Lipid Metabolism Disorders; Appetitive Behavior

Summary: cbd may affect metabolic control and energy intake. however, there is currently little data regarding these specific outcomes in humans. therefore, this study will investigate whether a single 300 mg dose of cbd can improve metabolic control following a meal and/or reduce energy intake at a subsequent meal. healthy, adult volunteers will complete two conditions in a crossover design, comparing outcomes following both cbd and placebo supplementation.


Eligibility criteria:
inclusion criteria: • self-report as healthy, male or female, aged 18-50, body mass index ≥18.5 and \<30.0 exclusion criteria: * currently engage in \>10 hours moderate or vigorous intensity physical activity per week * have consumed cbd or cannabis at all within the past two months * have used cbd or cannabis regularly (\>2x in a week) within the past four months * are suffering from any clinically significant illness * have regularly used tobacco within the previous 6 months (\> 2/week) * currently use any prescription or over-the-counter medications (except for hormonal contraception and simple painkillers) * have given a standard blood donation within 30 days of screening * are currently pregnant or lactating * are allergic/intolerant to any ingredients in food items provided during the study
autoreactive b cells in membranous nephropathy

Conditions: Membranous Nephropathy

Summary: membranous nephropathy (mn) is the most frequent cause of nephrotic syndrome (ns) in adults. the majority of mn patients show detectable circulating antibodies against the m-type phospholipase a2 receptor (pla2r). infusion of anti-cd20 monoclonal antibodies results in a profound depletion of b-cells, which are thought to be responsible for anti-pla2r production. b-cell depletion is followed by ns remission in 70% of cases. limited evidence highlighted that differences in the b- and t-cell compartments may exist between responders and non-responders. owing to the non-homogenous efficacy of anti-cd20 treatment, investigators hypothesize that in mn patients who experience ns remission after b-cell depleting therapy, autoreactive b-cells may be mostly circulating, whereas in patients who do not respond to the same treatment, autoreactive b-cells may chiefly reside into secondary lymphoid organs - and thus be more resistant to the drug action. researchers will therefore extensively analyze the circulating immune repertoire of mn patients before and after the infusion of b-cell lineage depleting agents, assessing the presence of circulating pla2r autoreactive b cells from appropriately stratified responder and non-responder patients. patients and healthy controls will be enrolled in this study. patients will be stratified according to gender, anti-pla2r status, type of b-cell lineage depleting agent received and response to treatment.


Eligibility criteria:
inclusion criteria: patients inclusion criteria * males and females. * adults (\> 18 years old). * patients with biopsy-proven idiopathic mn, who are candidate to receive (prospective cohort) or who already received (retrospective cohort) a b-cell depleting treatment as per center clinical practice. * mental state is such that they are able to understand and give valid consent to the study; * written informed consent according to the guidelines of the declaration of helsinki. healthy volunteers inclusion criteria * male and female (\>18 years) not known to suffer of any significant illness; * not assuming any medication or drug on a regular basis; * negative urine analysis (urine dipstick, multistick); * written informed consent according to the guidelines of the declaration of helsinki exclusion criteria: patients exclusion criteria * reasonable possibility of a secondary cause of mn (e.g.systemic lupus erythematosus, active hepatitis b, malignancy, drugs such as gold salts and penicillamine). * legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent. healthy volunteers exclusion criteria - legal incapacity, intellectual disability/mental retardation, dementia, uncooperative attitude or any other evidence that patient will not be able to understand the study procedures and aims and to give written informed consent.

Keywords: membranous nephropathy b cells anti-pla2r anti-cd20 antibodies
reducing hippocampal hyperactivity and improving cognition in schizophrenia

Conditions: Schizophrenia

Summary: this study plans to learn more about the effects of levetiracetam (lev) on brain activity and cognition in schizophrenia and schizoaffective disorder. levetiracetam is an anti-seizure drug, also called an anticonvulsant.

cognitive symptoms are not currently well-managed in veterans with schizophrenia, leading to substantially diminished quality of life. improved treatment strategies clearly are needed. recent studies suggest taht an overactive hippocampus is associated with cognitive deficits in the illness. based on findings that the anti-epileptic drug levetiracetam (lev) reduces hippocampal activity and improves cognition in other clinical populations while being safe and well-tolerated, this study will examine the effects of the drug on hippocampal activity and cognition in veterans with schizophrenia. in this crossover design, participants will take lev for 4 weeks and placebo pills for 4 weeks, but will not know the order in which they are taking them.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * good general health * normal vital signs (blood pressure, pulse, respiration) exclusion criteria: * substance abuse * significant neurological disorders * significant head trauma/injury * pregnancy * mri-specific exclusion criteria, e.g.,: * claustrophobia * weight\>400 lbs * metal in the body

Keywords: schizophrenia
effects of early mobility protocols in cardiac icu

Conditions: CABG

Summary: in this study the investigator aim to find the effects of early mobility on different physical activity protocols in post cabg patients. physical activity, functional status, functional capacity, kinesiophobia, icu mortality, heart rate, blood pressure, oxygen saturation, length of hospital stay and sternal instability. to compare the physical activity protocol used by physical therapist.

current study will compare two different early mobility protocols and will help in assessing best protocol to be use in cardiac icu for better outcomes of patients.

Eligibility criteria:
inclusion criteria: * age 40-70 years * both genders * extubated patients with no complication * post cabg (elective) * vitally stable * 1st cabg * selective cabg surgeries exclusion criteria: * post anesthesia psychosis * corrective surgeries * post cabg stroke * infectious wound * participants with a physical disability * intra-aortic balloon pump (iabp)

Keywords: early mobility physical activity kinesiophobia functional capacity
beovu versus eylea in the treatment of age-related macular neovascular degeneration

Conditions: Macula Lutea Degeneration

Summary: age-related macular neovascularization degeneration occur is a vision threatening condition. the investigators compare the efficacy of beovu and eylea intravitreal treatment in the management.

baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. procedure included randomized intravitreal injection of brolucizumab (beovu®, genentech, south francisco, ca) and of aflibercept (eylea; regeneron, tarrytown,ny)

Eligibility criteria:
inclusion criteria: * • age-related macular neovascularization degeneration exclusion criteria: * other causes of macular neovascularization degeneration * other macular diseases

Keywords: macular degeneration beovu eylea
study evaluating the impact of mesh pore size on chronic pain after lichtenstein hernioplasty

Conditions: Inguinal Hernia

Summary: the aim of the present study is to determine whether usage of mesh with larger pores, compared with mesh with smaller pores, would result in decreased rate of chronic pain after open inguinal hernia repair.

the aim of the present study is to determine whether usage of mesh with larger pores, compared with mesh with smaller pores, would result in decreased rate of chronic pain after open inguinal hernia repair. the patients are randomized into two study gropus receiving mesh with different pore size. clinical follow-up examination will be performed 1 week, 1 month, 6 months and 3 years after the operation.

Eligibility criteria:
inclusion criteria: * age ≥18 years * unilateral primary reducible inguinal hernia * elective operation * consent to participate in the study. exclusion criteria: * age \<18 years * irreducible * strangulated * recurrent hernia * inability to understand the questionnaire * unwillingness to participate in the study

Keywords: inguinal hernia chronic pain mesh lichtenstein hernioplasty
the diagnostic assessment and intervention study of amphetamine type stimulus

Conditions: Amphetamine Addiction

Summary: the purpose of this research is to inspire new medical ideas using brain image technology for the treatment of amphetamine type stimulus addition, at the same time lowing the addition damage.

the study will increase the sample size based on the preliminary work,also, establish drug dependence induced craving associated environmental experiments , by using the multi-lead biofeedback instrument , cogstate tester, event-related potentials recorder and 3.0t high-field magnetic resonance imaging system to record the physiology , electrophysiology and brain changes during craving, taking a subjective self-assessment , clinical observations and physiological responses combined system to evaluate the ats addiction degree.

Eligibility criteria:
inclusion criteria: * no previous history of any mental disorder meet the dsm-iv diagnosis * aged 18-49 years old , men and women * junior high school or higher education * use of amphetamine-type substances time for more than one year * cumulative use of amphetamines, substances dose of 50 grams or more. exclusion criteria: * current or past had suffered neurological diseases * exclusion of antisocial personality disorder and borderline personality disorder * addicts in addition to other substances in tobacco , coffee, social drinking outside * aids virus (hiv) detection positive patients .

Keywords: drug carving changes during rehabilitation community dna